 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «12...123124125126127128129130131132133134135 |
- | chloroquine phosphate / Generic mfg.
Trial completion date, Trial primary completion date: The Addition of Chloroquine to Chemoradiation for Glioblastoma, (clinicaltrials.gov) - Mar 21, 2018
P2, N=156, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2022
- | chloroquine phosphate / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Mar 21, 2018
P1, N=13, Recruiting, Sponsor: Maastricht Radiation Oncology
Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2020 --> Jan 2022 Active, not recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Jul 2018 --> May 2019
- | Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date: Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia (clinicaltrials.gov) - Feb 23, 2018
P1, N=1, Terminated, Sponsor: Alison Sehgal, MD, MS
Active, not recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Jul 2018 --> May 2019 N=36 --> 1 | Initiation date: Nov 2015 --> Aug 2016 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Sep 2016 | Trial completion date: Mar 2023 --> Oct 2017; Inability to accrue
- | hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Feb 6, 2018
P1/2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=36 --> 1 | Initiation date: Nov 2015 --> Aug 2016 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Sep 2016 | Trial completion date: Mar 2023 --> Oct 2017; Inability to accrue Trial primary completion date: Dec 2017 --> Dec 2018
- | chloroquine phosphate / Generic mfg.
Enrollment closed: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Aug 22, 2017
P1, N=7, Active, not recruiting, Sponsor: Maastricht Radiation Oncology
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Aug 21, 2017
P1, N=48, Recruiting, Sponsor: Sukeshi Patel
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2017 --> Jul 2018
- | Enrollment open, Trial initiation date: Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia (clinicaltrials.gov) - Jul 31, 2017
P1, N=36, Recruiting, Sponsor: Alison Sehgal, MD, MS
Trial primary completion date: Jul 2017 --> Jul 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Nov 2015
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - Jul 17, 2017
P1, N=143, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Nov 2015 Recruiting --> Active, not recruiting | N=224 --> 143 | Trial primary completion date: Apr 2018 --> Apr 2019
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Apr 27, 2017
P1, N=48, Recruiting, Sponsor: Devalingam Mahalingam
Recruiting --> Active, not recruiting | N=224 --> 143 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial primary completion date: Jan 2017 --> Jul 2017
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=35, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Jan 2017 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Nov 2016
- hydroxychloroquine / Generic mfg.
Trial completion, Enrollment change, Surgery, Metastases: Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=20, Completed, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Nov 2016 Active, not recruiting --> Completed | N=15 --> 20
- hydroxychloroquine / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Surgery: Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=4, Terminated, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed | N=15 --> 20 N=30 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Feb 2016; slow accrual
- hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Jan 26, 2017
P1/2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=30 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Feb 2016; slow accrual Trial primary completion date: Dec 2016 --> Dec 2017
- hydroxychloroquine / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment closed: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) - Dec 7, 2016
P1/2, N=40, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=35, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2016
P1, N=48, Recruiting, Sponsor: Devalingam Mahalingam
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Jan 2016 --> Jan 2017
- chloroquine phosphate / Generic mfg.
Enrollment open: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Aug 2, 2016
P1, N=9, Recruiting, Sponsor: Maastricht Radiation Oncology
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- hydroxychloroquine / Generic mfg.
Trial primary completion date, Surgery: Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance (clinicaltrials.gov) - Jul 19, 2016
P0, N=30, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- chloroquine phosphate / Generic mfg.
Trial initiation date, Trial primary completion date: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Jun 5, 2016
P1, N=9, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
Trial primary completion date: Apr 2016 --> Apr 2017 Initiation date: Feb 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Jul 2018
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - Apr 26, 2016
P1, N=236, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Feb 2016 --> Jul 2016 | Trial primary completion date: Jan 2018 --> Jul 2018 Trial primary completion date: Apr 2017 --> Apr 2018
- reparixin (DF 1681Y) / Dompe
Trial primary completion date, IO biomarker, Surgery: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=20, Terminated, Sponsor: Domp
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Oct 2015 --> Mar 2015
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2016
P1/2, N=35, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Oct 2015 --> Mar 2015 N=25 --> 35
- New P1 trial: Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia (clinicaltrials.gov) - Dec 16, 2015
P1, N=36, Not yet recruiting, Sponsor: Alison Sehgal, MD, MS
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2015
P1/2, N=25, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=25 --> 35 Trial primary completion date: Sep 2013 --> Sep 2016
- hydroxychloroquine / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment change, Trial primary completion date: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) - Dec 9, 2015
P1/2, N=35, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Sep 2013 --> Sep 2016 N=25 --> 35 | Trial primary completion date: Sep 2014 --> Sep 2016
- hydroxychloroquine / Generic mfg.
Enrollment closed, Surgery: Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance (clinicaltrials.gov) - Nov 5, 2015
P0, N=30, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
N=25 --> 35 | Trial primary completion date: Sep 2014 --> Sep 2016 Recruiting --> Active, not recruiting
- reparixin (DF 1681Y) / Dompe
Enrollment change, Trial termination, IO biomarker, Surgery: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=20, Terminated, Sponsor: Domp
Recruiting --> Active, not recruiting N=40 --> 20 | Active, not recruiting --> Terminated; Enrollment target not reached
- chloroquine phosphate / Generic mfg.
Trial completion, Enrollment change: "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" (clinicaltrials.gov) - Oct 20, 2015
P4, N=10, Completed, Sponsor: Shiraz University of Medical Sciences
N=40 --> 20 | Active, not recruiting --> Terminated; Enrollment target not reached Recruiting --> Completed | N=20 --> 10
- chloroquine phosphate / Generic mfg.
Trial initiation date: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Sep 24, 2015
P1, N=9, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
Recruiting --> Completed | N=20 --> 10 Initiation date: Aug 2015 --> Dec 2015
- hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Initiation date: Aug 2015 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- hydroxychloroquine / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery, Metastases: Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery (clinicaltrials.gov) - May 22, 2015
P0, N=15, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Dec 2014 --> Dec 2016 Suspended --> Active, not recruiting | Trial primary completion date: Dec 2013 --> May 2013
- reparixin (DF 1681Y) / Dompe
Enrollment closed, IO biomarker, Surgery: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer (clinicaltrials.gov) - May 7, 2015
P2, N=40, Active, not recruiting, Sponsor: Domp
Suspended --> Active, not recruiting | Trial primary completion date: Dec 2013 --> May 2013 Recruiting --> Active, not recruiting
- | chloroquine phosphate / Generic mfg.
New P2 trial: The Addition of Chloroquine to Chemoradiation for Glioblastoma, (clinicaltrials.gov) - May 4, 2015
P2, N=156, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - Apr 23, 2015
P1, N=236, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- chloroquine phosphate / Generic mfg.
New P1 trial: CHLOROBRAIN: The Addition of Chloroquine to Chemoradiation for Glioblastoma (clinicaltrials.gov) - Mar 5, 2015
P1, N=9, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Jan 18, 2015
P1, N=48, Recruiting, Sponsor: Devalingam Mahalingam
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Apr 2014 --> Jan 2016
- reparixin (DF 1681Y) / Dompe
Trial primary completion date, IO biomarker, Surgery: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer (clinicaltrials.gov) - Oct 30, 2014
P2, N=40, Recruiting, Sponsor: Domp
Trial primary completion date: Apr 2014 --> Jan 2016 Trial primary completion date: Feb 2014 --> Sep 2015
- Sutent (sunitinib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Oct 23, 2014
P1, N=21, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2014 --> Sep 2015 N=40 --> 21 | Trial primary completion date: Oct 2014 --> Jul 2013
- Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Jul 30, 2014
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 21 | Trial primary completion date: Oct 2014 --> Jul 2013 Trial primary completion date: Jul 2014 --> Oct 2014
- Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Apr 17, 2014
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Oct 2014 N=21 --> 40
- chloroquine phosphate / Generic mfg.
New P4 trial: "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" (clinicaltrials.gov) - Feb 5, 2014
P4, N=20, Recruiting, Sponsor: Shiraz University of Medical Sciences
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Sep 15, 2013
P1, N=48, Recruiting, Sponsor: Devalingam Mahalingam
N=21 --> 40 N=30 --> 48
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: Hydroxychloroquine + Vorinostat in Advanced Solid Tumors (clinicaltrials.gov) - Sep 15, 2013
P1, N=48, Recruiting, Sponsor: Devalingam Mahalingam
N=30 --> 48 Active, not recruiting --> Recruiting
- hydroxychloroquine / Generic mfg.
Trial suspension, Surgery, Metastases: Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 22, 2013
P0, N=15, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Recruiting Recruiting --> Suspended
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (clinicaltrials.gov) - Jun 30, 2013
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Active, not recruiting
- reparixin (DF 1681Y) / Dompe
New P2 trial, IO biomarker, Surgery: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer (clinicaltrials.gov) - May 21, 2013
P2, N=40, Recruiting, Sponsor: Domp
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer (clinicaltrials.gov) - Sep 20, 2012
P1, N=236, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=160 --> 236
- hydroxychloroquine / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
New P1/2 trial: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (clinicaltrials.gov) - Jan 11, 2012
P1/2, N=25, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- hydroxychloroquine / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P1/2 trial, Combination therapy: A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer (clinicaltrials.gov) - Jan 8, 2012
P1/2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania